Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study

K. Pavelka, AJ. Kivitz, E. Dokoupilova, R. Blanco, M. Maradiaga, H. Tahir, Y. Wang, BO. Porter, A. Stefanska, HB. Richards, S. Rohrer, MEASURE 3 study group,

. 2020 ; 2 (2) : 119-127. [pub] 20200120

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005337

Grantová podpora
Novartis

OBJECTIVE: Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years. Here, we report end-of-study 3-year efficacy and safety results of secukinumab 150 and 300 mg from the MEASURE 3 study. METHODS: A total of 226 patients was randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous (s.c.) secukinumab 300/150 mg every 4 weeks or a matched placebo. At week 16, placebo patients were re-randomized to s.c. secukinumab 300/150 mg. Analysis at week 156 included patients initially randomized to secukinumab and those who switched from placebo to secukinumab at week 16 (any secukinumab 300/150 mg). Outcome measures at week 156 included Assessment of Spondyloarthritis International Society (ASAS) 20/40, Bath Ankylosing Spondylitis Disease Activity Index, ASAS partial remission (PR), ASAS 5/6, and Ankylosing Spondylitis Disease Activity Score-C-reactive protein inactive disease. RESULTS: The retention rates from weeks 16 to 156 were 80.5% and 80.9% in secukinumab 300 and 150 mg, respectively. ASAS 20/40 response rates at week 156 were 75.0%/56.5% and 68.2%/47.7% for secukinumab 300 and 150 mg, respectively. At week 156, response rates on more stringent clinical end points (eg, ASAS 40, ASAS-PR) were higher with the 300-mg dose, particularly in tumor necrosis factor (TNF)-inadequate responder (IR) patients. No new safety findings were observed. CONCLUSION: Secukinumab (300 and 150 mg) provided sustained improvements through 3 years in the signs and symptoms of active AS. Improvements with secukinumab 300 mg were numerically higher compared with the 150-mg dose for some higher hurdle end points and in TNF-IR patients. The safety profile of secukinumab was consistent with previous reports.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005337
003      
CZ-PrNML
005      
20210121124719.0
007      
ta
008      
200511s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/acr2.11102 $2 doi
035    __
$a (PubMed)31957970
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pavelka, Karel $u Charles University in Prague, Czech Republic.
245    10
$a Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study / $c K. Pavelka, AJ. Kivitz, E. Dokoupilova, R. Blanco, M. Maradiaga, H. Tahir, Y. Wang, BO. Porter, A. Stefanska, HB. Richards, S. Rohrer, MEASURE 3 study group,
520    9_
$a OBJECTIVE: Secukinumab 150 mg has demonstrated significant improvement in signs and symptoms of ankylosing spondylitis (AS), with response rates sustained for up to 5 years. Here, we report end-of-study 3-year efficacy and safety results of secukinumab 150 and 300 mg from the MEASURE 3 study. METHODS: A total of 226 patients was randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous (s.c.) secukinumab 300/150 mg every 4 weeks or a matched placebo. At week 16, placebo patients were re-randomized to s.c. secukinumab 300/150 mg. Analysis at week 156 included patients initially randomized to secukinumab and those who switched from placebo to secukinumab at week 16 (any secukinumab 300/150 mg). Outcome measures at week 156 included Assessment of Spondyloarthritis International Society (ASAS) 20/40, Bath Ankylosing Spondylitis Disease Activity Index, ASAS partial remission (PR), ASAS 5/6, and Ankylosing Spondylitis Disease Activity Score-C-reactive protein inactive disease. RESULTS: The retention rates from weeks 16 to 156 were 80.5% and 80.9% in secukinumab 300 and 150 mg, respectively. ASAS 20/40 response rates at week 156 were 75.0%/56.5% and 68.2%/47.7% for secukinumab 300 and 150 mg, respectively. At week 156, response rates on more stringent clinical end points (eg, ASAS 40, ASAS-PR) were higher with the 300-mg dose, particularly in tumor necrosis factor (TNF)-inadequate responder (IR) patients. No new safety findings were observed. CONCLUSION: Secukinumab (300 and 150 mg) provided sustained improvements through 3 years in the signs and symptoms of active AS. Improvements with secukinumab 300 mg were numerically higher compared with the 150-mg dose for some higher hurdle end points and in TNF-IR patients. The safety profile of secukinumab was consistent with previous reports.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kivitz, Alan J $u Altoona Center for Clinical Research, Duncansville, Pennsylvania.
700    1_
$a Dokoupilova, Eva $u Medical Plus s.r.o., Uherske Hradiste, and University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
700    1_
$a Blanco, Ricardo $u Hospital Universitario Marqués de Valdecilla, Santander, Spain.
700    1_
$a Maradiaga, Marco $u Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, México.
700    1_
$a Tahir, Hasan $u Barts Health National Health Service (NHS) Trust, London, UK.
700    1_
$a Wang, Yi $u Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
700    1_
$a Porter, Brian O $u Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
700    1_
$a Stefanska, Anna $u Novartis Ireland Limited, Dublin, Ireland.
700    1_
$a Richards, Hanno B $u Novartis Pharma AG, Basel, Switzerland.
700    1_
$a Rohrer, Susanne $u Novartis Pharma AG, Basel, Switzerland.
710    2_
$a MEASURE 3 study group
773    0_
$w MED00203195 $t ACR open rheumatology $x 2578-5745 $g Roč. 2, č. 2 (2020), s. 119-127
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31957970 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20210121124718 $b ABA008
999    __
$a ind $b bmc $g 1524267 $s 1095392
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 2 $c 2 $d 119-127 $e 20200120 $i 2578-5745 $m ACR open rheumatology $n ACR Open Rheumatol $x MED00203195
GRA    __
$p Novartis
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace